Cargando…
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
Tirapazamine (TPZ, SR4233, WIN 59075) is a bioreductive drug that is activated in regions of low oxygen tension to a cytotoxic radical intermediate. This labile metabolite shows high selective toxicity towards hypoxic cells, such as those found in solid tumours. Under aerobic conditions, redox cycli...
Autores principales: | Saunders, M P, Patterson, A V, Chinje, E C, Harris, A L, Stratford, I J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363339/ https://www.ncbi.nlm.nih.gov/pubmed/10682679 http://dx.doi.org/10.1054/bjoc.1999.0977 |
Ejemplares similares
-
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
por: Patterson, A. V., et al.
Publicado: (1997) -
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995) -
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
por: Chinje, E C, et al.
Publicado: (1999) -
Effects of Diminished NADPH:cytochrome P450 Reductase in Human Hepatocytes on Lipid and Bile Acid Homeostasis
por: Heintze, Tamara, et al.
Publicado: (2021) -
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)